HTG Molecular Presenting at Upcoming Healthcare Conferences
TUCSON, Ariz., Nov. 12, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview the Canaccord Medical Technology & Diagnostics conference being held November 15, 2018 at the Westin St. Francis Hotel in New York City, and Shaun McMeans, Chief Financial Officer, will meet with investors on a 1x1 basis at the Craig Hallum Alpha Select Conference being held November 15, 2018 at the Sheraton New York Times Square Hotel. Details of both meetings are as follows:
Canaccord Medical Technology & Diagnostics Conference Date: Thursday, November 15 Time: 11:00 am Eastern Time Location: Westin St. Francis Hotel Craig Hallum Alpha Select Conference Date: Thursday, November 15 Time: 1x1 meetings Location: Sheraton New York Times Square Hotel
About HTG:HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
Ashley R. RobinsonLifeSci Advisors, LLCPhone: (617) 535-7742Email: firstname.lastname@example.org
TJ Johnson Chief Executive Officer HTG Molecular Diagnostics Email: email@example.com